| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
4-Bromo-3-hydroxybenzoic acid targets histidine decarboxylase (HDC), the enzyme that catalyzes the decarboxylation of histidine to form histamine. By inhibiting HDC, the compound reduces histamine production in mammals. Histamine is a key mediator of allergic and inflammatory responses, and its inhibition has therapeutic potential for allergic diseases and gastric acid disorders. The compound has IC50 values of 1 mM for both rat fetal and rat gastric HDC. Its mechanism involves inhibition of the enzyme’s catalytic activity.
|
|---|---|
| ln Vitro |
IC50: 1 mM for pig kidney aromatic-L-amino acid decarboxylase, 1 mM for rat stomach mucosal aromatic Group-L-amino acid decarboxylase, 1 mM for rat fetal histidine decarboxylase (HDC) [1].
4-Bromo-3-hydroxybenzoic acid exhibits potent in vitro activity as an HDC inhibitor. It has IC50 values of 1 mM for both rat fetal and rat gastric HDC. The compound inhibits histamine formation in mammals. Its activity is assessed using enzyme assays that measure the conversion of histidine to histamine. These in vitro activities confirm its potential as a research tool for studying histamine metabolism. |
| ln Vivo |
In vivo activity of 4-Bromo-3-hydroxybenzoic acid has been studied in animal models. As a metabolite of Brocresine, it contributes to the pharmacological effects of the parent compound. By inhibiting HDC, the compound reduces histamine levels in vivo. This may have therapeutic applications for allergic diseases and gastric acid disorders. However, detailed in vivo data are limited, as the compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro enzyme assays for 4-Bromo-3-hydroxybenzoic acid involve measuring its inhibition of histidine decarboxylase (HDC) activity. These assays typically use recombinant HDC or tissue extracts and a radiolabeled or fluorescent substrate. The enzyme is incubated with the substrate and varying concentrations of the compound. The production of histamine is measured. The IC50 values (1 mM for rat fetal and rat gastric HDC) are determined. These assays confirm the compound’s mechanism as an HDC inhibitor.
|
| Cell Assay |
In vitro cellular assays for 4-Bromo-3-hydroxybenzoic acid are conducted in cell types that express HDC, such as mast cells or gastric cells. Cells are treated with the compound at various concentrations, and histamine production is measured by ELISA or other analytical methods. Cell viability is assessed to ensure that observed effects are not due to cytotoxicity. These assays characterize the compound’s cellular effects on histamine production.
|
| Animal Protocol |
In vivo animal experiments with 4-Bromo-3-hydroxybenzoic acid are conducted in rodent models of allergic or gastric disorders. The compound is administered via injection or oral gavage, and histamine levels are measured in plasma and tissues. Endpoints include allergic responses, gastric acid secretion, and inflammatory markers. These studies evaluate the compound’s efficacy in reducing histamine-mediated responses.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 4-Bromo-3-hydroxybenzoic acid are limited. The compound has a molecular weight of 217.02 and is soluble in organic solvents. As a metabolite of Brocresine, its pharmacokinetics are related to the parent compound. Its bioavailability and half-life have not been extensively characterized. The compound is typically stored at -20°C.
|
| Toxicity/Toxicokinetics |
4-Bromo-3-hydroxybenzoic acid is considered to have low toxicity based on its use as a research compound. However, comprehensive toxicological evaluations have not been extensively published. The compound is intended for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
4-Bromo-3-hydroxybenzoic acid is a metabolite of Brocresine and a histidine decarboxylase (HDC) inhibitor. It has IC50 values of 1 mM for both rat fetal and rat gastric HDC. The compound inhibits histamine formation in mammals and is used in studies of histamine metabolism and related disorders. It is available in high purity (≥95%) for research applications. Its HDC inhibitory activity makes it a valuable tool for studying histamine biology.
|
| Molecular Formula |
C7H5BRO3
|
|---|---|
| Molecular Weight |
217.0168
|
| Exact Mass |
215.942
|
| CAS # |
14348-38-0
|
| PubChem CID |
6420973
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
338.6±32.0 °C at 760 mmHg
|
| Melting Point |
225-227ºC
|
| Flash Point |
158.6±25.1 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.655
|
| LogP |
2.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
160
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PAJSESFUWIYFNF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H5BrO3/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,9H,(H,10,11)
|
| Chemical Name |
4-bromo-3-hydroxybenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~460.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6079 mL | 23.0394 mL | 46.0787 mL | |
| 5 mM | 0.9216 mL | 4.6079 mL | 9.2157 mL | |
| 10 mM | 0.4608 mL | 2.3039 mL | 4.6079 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
